The cyclo-oxygenase (COX) pathway converts arachidonic acid to prostaglandins, prostaBackground -There are two isoforms of cyclin, and thromboxane A 2 . 1 2 There are two cyclo-oxygenase (COX), namely COX-1 isoforms of COX, namely COX-1 and COX-2.
Methods subject was taking regular nasal corticosteroids (table 2) . All asthmatic subjects were using  Ten normal volunteers (seven men) of mean inhaled or oral 2 agonists as required. All subjects underwent skin prick tests to common (SE) age 23 (1) years and 18 asthmatic patients (12 men) of mean (SE) 39 (3) years with forced aeroallergens and atopy was defined as the presence of at least two positive reactions (weals expiratory volume in one second (FEV 1 ) of 90.9 (4.8)% were studied, of whom 11 had of 3 mm or more compared with saline control) to cat fur, dog hair, grass pollen, and Dermaaspirin-sensitive asthma (ASA) and the remainder had non-aspirin-sensitive asthma tophagoides pteronyssinus.
Bronchoscopic examination was performed (NASA). The diagnosis of aspirin sensitivity was made on the basis of history and confirmed and biopsy samples of the airway mucosa were taken as previously described 14 at least one by a 20% or greater fall in FEV 1 following lysine aspirin inhalation challenge as previously month after aspirin provocation. Bronchial biopsy samples were immediately snap frozen in described.
14 The NASA group also underwent lysine aspirin challenge and, if negative, this embedding medium and stored at −70°C until analysed. All subjects provided written and was confirmed by incremental challenge with 600 mg of aspirin given orally.
informed consent and the study was approved by the Hochgesbirgsklinik, Davos-Wolfgang The ASA subjects (seven men, six atopic) had a mean (SE) age of 43 (4) years with a ethics committee. mean FEV 1 of 94.6 (4.2)% and the seven NASA subjects (five men, six atopic) had a mean age of 34 (4) years with a mean FEV 1 of  Immunohistochemistry was performed as pre-85.1 (10.7)%. Of the 11 subjects with ASA two were taking prednisolone orally, 10 were viously described 14 using the avidin biotin complex (ABC) technique for single immunotaking regularly inhaled corticosteroids, and four were using regular nasal corticosteroids staining and the ABC technique combined with the indirect alkaline phosphatase technique for (table 1) . Of the seven subjects with NASA one was using prednisolone orally, four were the double immunostaining. Affinity purified rabbit polyclonal anti-COX-1 or anti-COX-2 using regular inhaled corticosteroids, and one group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from
Figure 1 (A) Asthmatic airway stained with COX-1 polyclonal antibody. The photograph shows minimal staining of the airway epithelium and two inflammatory cells which have stained for COX-1. (B) Asthmatic airway stained with COX-2 polyclonal antibody. The photograph shows significant staining of airway epithelial cells and submucosal inflammatory cells. The submucosal cells have been double stained for COX-2 and for macrophages with a monoclonal antibody to macrophages (EBM11).
(gift from Dr Jilly Evans, Merck Frosst, Ca-colour reaction was developed by incubation with diaminobenzidine, which produces a nada) were used at a dilution of 1/1000. All the primary antibodies used for cell identification brown precipitate, and 5-bromo-4-chloro-3-indolyl phosphate/ nitroblue tetrazolium were mouse monoclonal IgG 1 antibodies and comprised the following: AA1 (DAKO, High (Sigma, Poole, Dorset, UK) which produces a blue precipitate. A positive control using nasal Wycombe, UK), a mast cell tryptase marker used at a dilution of 1/50; EBM11 (DAKO), a polyp tissue and a negative control without primary antibody was included in each staining pan-macrophage marker that recognises CD68 used at 1/100 dilution; anti-CD3 (DAKO), a run. pan-T lymphocyte marker used at 1/50 dilution; NP57 (DAKO), an anti-human neutrophil elastase antibody used at 1/600 dilution;  
The hue-saturation-intensity method of colour BMK13 (Cymbus Bioscience Ltd, Chilworth, UK), a pan-eosinophil marker that recognises image analysis was adopted for detection of the brown immunoperoxidase reaction product, as major basic protein used at 1/40 dilution. The secondary antibodies were a goat anti-mouse previously described. 18 The total epithelial area in each biopsy specimen was measured. alkaline phosphatase conjugated antibody (Sera-lab, Crawley Down, UK) used at a di-
The numbers of specific cells were counted on the entire submucosal biopsy area by a lution of 1/100 and a swine anti-rabbit biotinylated antibody (DAKO) used at a dilution blinded investigator. The total section area was measured using the image analyser and all cell of 1/200. Single staining was performed on the frozen bronchial biopsy specimens with the counts were expressed as cells /mm 2 . rabbit polyclonal antibody to COX-1.
The biopsies were double immunostained using a rabbit polyclonal antibody to COX-2   Statistical analysis of the COX-1 and COX-2 concurrently with one monoclonal antibody to each cell type: neutrophils (NP57); macro-data was performed by the Mann-Whitney U test, using Minitab Software (Minitab Inc.) phages (EBM11); eosinophils (BMK13); mast cells (AA1); and T lymphocytes (anti-CD3). Results are expressed as mean (SE). Staining for COX-1 was by the ABC technique as previously described 14 with the modification that incubation with the two secondary anti-Results   -1  -2  bodies were made separately and for 30 minutes each. Endogenous biotin, alkaline phosphatase   There was no significant difference in the epiand peroxidase activity was abolished as previously described.
14 The immunoperoxidase thelial expression of COX-1 between normal
shows an example of an asthmatic airway stained for COX-1. In contrast, there was a mean fourfold increase in the bronchial epithelial expression of COX-2 in asthmatic subjects (p=0.002; fig 2A) , but there was no significant difference in the bronchial epithelial expression of COX-2 between subjects with ASA and NASA (p=0.79). Figure 1B shows an example of an asthmatic airway stained for COX-2.
  -1  -2    There was no significant difference between the number of COX-1 positive cells in the submucosa of normal and asthmatic subjects , respectively, p=0.31). In contrast, there was a significant mean 14-fold increase in the number of COX-2 positive cells in the submucosa from asthmatic subjects (p=0.0001; fig 2B) , but there was no significant difference between the total number of COX-2 positive cells in the bronchial submucosa from subjects with ASA and NASA (180.9 (54.5) cells/mm 2 
    -2
effects such as gastric and renal damage. The There was a significant mean sixfold increase two COX isoenzymes are pharmacologically in the numbers of mast cells expressing COX-distinct. 7 For example, aspirin completely 2 (p=0.004) between subjects with ASA and inhibits bis-oxygenation of arachidonate by NASA (56.2 (12.7) cells/mm 2 and 9.0 (2.0) COX-1, while aspirin treated COX-2 metacells/mm 2 , respectively). There was also a sig-bolises arachidonate primarily to 15-lipoxynificant mean twofold increase in the per-genase-derived metabolites such as 15-hydroxycentage of mast cells expressing COX-2 (p= eicosatetraenoic acid (15-HETE), instead 0.008) and a mean fourfold increase in the of PGH 2 , due to acetylation of COX-2 by percentage of COX-2-expressing cells that were aspirin. 24 15-HETE could affect the function mast cells (p=0.006) in subjects with ASA of any of a number of cells and tissues involved compared with NASA ( fig 3A and B) .
in homeostasis and inflammation. Aspirin, There was a significant mean 2.5-fold in-indomethacin, and piroxicam are more potent crease in the number of total eosinophils ex-at inhibiting COX-1, whereas flurbiprofen, pressing COX-2 (p=0.044) between subjects meclofenamate, and diclofenac are equipotent with ASA and NASA (104.8 (29.7) cells/mm 2 at inhibiting COX-1 and COX-2. and 39.9 (7.9) cells/mm 2 , respectively). The
There are no previous reports of the expercentage of total eosinophils expressing pression of COX-1 and COX-2 isoenzymes in COX-2 and the percentage of COX-2 cells that bronchial asthma. We have shown that asthwere eosinophils was also raised in subjects matic bronchial epithelium and submucosal with ASA but the difference failed to reach inflammatory cells have enhanced expression statistical significance (p=0.212 and p=0.058, of COX-2, suggesting that the quantities and respectively; fig 4A and B) .
profile of COX-2-derived metabolites may be There was no significant difference in the important in the amplification of the inexpression of COX-2 in activated eosinophils, flammatory response in asthmatic airways. The neutrophils and macrophages of subjects with results were obtained by comparing biopsy ASA and NASA. T lymphocytes did not stain samples obtained by fibreoptic bronchoscopy for COX-2.
from asthmatic and normal control individuals. The mucosal biopsy samples were analysed using specific antibodies to each of the COX Discussion isoenzymes, as well as to individual cell types. COX exists in at least two isoforms with similar The use of double immunohistochemistry molecular weights (approximately 70 kDa).
19 allowed co-localisation of cyclo-oxygenase iso-COX-1 is involved in maintaining normal enzyme to specific cells. The levels of COX-1, physiological function of tissues -for example, the non-inducible isoform, did not increase in it produces prostacyclin which when released asthma, indicating that the inflammatory milieu by the endothelium is antithrombogenic 20 and in bronchial asthma does not affect its rewhen released by the gastric mucosa is cytogulation. Previous clinical observations that protective.
21 COX-2 expression is induced by non-steroidal anti-inflammatory drugs such as pro-inflammatory cytokines in vitro in cell types indomethacin and aspirin do not benefit the such as endothelial cells, macrophages, and majority of asthmatic patients have suggested fibroblasts 7 22 23 and in vivo its expression is that COX metabolites have little part to play augmented in inflamed lesions. 19 Non-steroidal in the mechanisms of airways inflammation. anti-inflammatory drugs inhibit the activity of However, the discovery of the inducible isoform COX, a property which explains both its theraof COX now demands a reinterpretation of peutic and adverse effect. The ability of nonthese clinical observations, especially since the steroidal anti-inflammatory drugs to inhibit airway microenvironment in asthma with the COX-2 may explain their therapeutic potential abundance of pro-inflammatory cytokines will as anti-inflammatory drugs, whereas inhibition of COX-1 may account for their unwanted side encourage the enhanced expression of COX- 
